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Introduction
John Steinbeck drew the title of his novel “Of Mice and 
Men” from a line in a Robert Burns poem “To a mouse”: “The 
best-laid plans of mice and men/Go often awry.” Unlike John 
Steinbeck who used the title to mirror the characters who were 
struggling during the Great Depression to the mouse whose 
nest was accidentally destroyed by the poet (Burns 1785), we 
chose this line to emphasize that the best-laid plan can go 
wrong in infectious disease control and prevention. Here, we 
will discuss the contributing factors behind the global successes 
and failures in the prevention and control of swine fevers—
classical swine fever (CSF) and African swine fever (ASF).
Swine Fevers (Classical Swine Fever and African 
Swine Fever) are not Swine Flu
Swine fevers and swine flu are different diseases caused by 
completely different viruses. However, swine fevers and swine 
flu are often regarded as the same disease by the public. This 
is in part due to the 2009 H1N1 influenza pandemic where the 
human influenza virus contained genetic segments from the 
swine influenza virus (Neumann et  al., 2009). Swine flu and 
human flu are caused by negative-strand RNA viruses (in-
fluenza A  virus). In contrast, CSF and African swine fever 
are caused by a small positive-strand RNA virus (CSF virus, 
CSFV) and a large double-strand DNA virus (ASF virus, 
ASFV), respectively. To date, no evidence suggests that ASFV 
and CSFV can infect humans, even though they often cause 
lethal infection in pigs of all ages. Various inactivated swine 
flu vaccines with different levels of efficacy are used on swine 
farms all over the world. On the other hand, safe and effica-
cious modified live virus (MLV) vaccines (such as the C-strain 
vaccine) have contributed to the successful control of CSF in 
many countries (Luo et al., 2014; Blome et al., 2017). But there 
is no safe and efficacious vaccine for ASF.
Vaccines and Diagnostics: Technological Tools 
for Infectious Disease Control and Prevention
Vaccines are the most cost-effective tools for animal infec-
tious disease control and prevention in disease-endemic regions. 
Implications
• Know your enemy (the disease and pathogen) through 
supporting innovative research. Government and the 
industry should invest strongly and continuously in 
research related to African swine fever. Important re-
search areas include African swine fever virus (ASFV) 
biology, ASFV-host interaction, point-of-contact 
diagnostics, safe and efficacious vaccines, swine farm 
biosafety and biosecurity risk management systems, 
and high containment facilities that are suitable for Af-
rican swine fever research.
• Science and technology alone are not enough without 
purpose and direction. All stakeholders of the swine in-
dustry should develop and enact science-based policies 
on foreign animal disease outbreak emergency man-
agement.
• To eradicate swine fevers, leaders of the swine indus-
try and governments should work together. Govern-
ments should ensure their goals and policies are fully 
supported by swine farm owners, farm employees, pork 
processing plants, animal health companies, veterinar-
ians, regulatory agencies, social media, and the public.
• The transboundary nature of emerging and re-
emerging high consequence animal infectious disease 
threats requires global cooperation. This international 
cooperation should be not only in outbreak manage-
ment, but also in research for a broader biomedical, 
social, and ecological understanding of disease sys-
tems.
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Based on the nature and/or production method of antigens, 
vaccines can be classified into five different categories: 1) tissue-
derived vaccines (inactivated or live) with little or no antigen 
purification; 2)  inactivated vaccines in which pathogens are 
inactivated by the chemical methods after they are processed 
from cell culture or fermentation systems; 3)  MLV vaccines 
with naturally or genetically modified attenuated live microbes; 
4) subunit vaccines in which the antigens are purified from na-
tive pathogen cultures or recombinant expression systems; and 
5) nucleotide (DNA and RNA) vaccines in which partial genetic 
segments from the pathogens are used to directly induce antigen 
expression in the immunized animal or incorporated into micro-
bial vectors for antigen expression and delivery.
The selection of  a certain type of  vaccine for field use 
in animal disease control and prevention should be based 
on its safety and efficacy profile and cost-effective analysis, 
not how the vaccine is produced. The first three categories 
(tissue-derived, inactivated, and MLV) of  vaccines have 
been used in the field since the late 1800s and the last two 
categories of  vaccines (subunit and nucleotide) were devel-
oped with new technologies in the last few decades (McVey 
and Shi, 2010). For many infectious diseases, one or more of 
the five types of  vaccines have been developed with robust 
and efficient manufacturing processes. Therefore, safe and 
efficacious vaccines are affordable and available for use in 
various animal populations.
In addition to vaccines, diagnostics are also essential 
tools for animal disease control and prevention. For antigen/
pathogen detection, antigen capture antibody enzyme-linked 
immunosorbent assay (ELISA), real-time quantitative poly-
merase chain reaction (PCR), lateral flow assay (LFA), and 
a fluorescent antibody test (FAT) are routinely used in a la-
boratory setting. Various forms (indirect, Sandwich, and com-
petitive) of ELISA have been developed to detect antigen/
pathogen-specific antibodies in animals after vaccination or 
infection. Virus serum neutralization assays (and surrogate as-
says like hemagglutination inhibition) are still very useful for 
characterizing antibody responses.
Diagnostics that can differentiate infected from vaccinated 
animals (DIVA) are crucial tools for animal disease control 
and eradication. DIVA assays are extremely useful for the con-
trol of a newly emerging infectious disease or a foreign animal 
disease as they can enable the “vaccinate-to-live” strategy by 
which vaccinated animals can be raised and processed for 
food production and consumption and/or international trade. 
Genetic DIVA assays are designed to identify the genetic differ-
ence between a vaccine antigen and a virulent field pathogen. 
Serological DIVA assays target the difference in host immune 
response to the vaccine strain (after vaccination) and virulent 
field strain (after infection).
Classical Swine Fever/Hog Cholera
What is classical swine fever?
Pigs with CSF, also known as hog cholera, have clinical signs 
such as high fever, loss of appetite, lethargy, and high mortality 
rate. CSF/hog cholera was first reported in the Ohio river valley 
in the 1830s, and it still causes significant economic losses to the 
swine industry in Asia and presents a significant agricultural 
security threat to CSF-free countries such as the United States. 
CSF is probably one of the earliest swine viral diseases iden-
tified by animal disease researchers in the early 20th century. 
It was the United States Department of Agriculture (USDA) 
scientists Emil Alexander de Schweinitz and Marion Dorset 
who first demonstrated in 1903 that the highly contagious hog 
cholera was caused by a virus (not a bacterium) and hogs that 
survived from the infection were immune from future infection 
(Lofflin, 2009).
CSF control and its impact on animal health regu-
lation in the United States
Hog cholera/CSF caused devastating losses to American 
swine producers since the late 1800s. According to USDA’s his-
torical data, “Outbreaks in 1886, 1887, and 1896 each killed 
more than 13% of the Nation’s hogs; more than 10% died 
during the 1913 outbreak. The disease was still costing pro-
ducers $50 million a year in the early 1960’s” (USDA 2019). 
Around the beginning of the 20th century, smoke rising aloft 
from the burning of dead pigs on farms across the prairies 
of the Midwest was the heart-breaking evidence of CSF de-
struction. It is not an overstatement that CSF was the most 
destructive disease of swine in the United States for more than 
a century (1830 to 1970).
Although the eradication of CSF from the United States in 
1978 was a great success story, one must remember that many 
important pieces of research were carried out before the 17-yr 
effort (1961 to 1978), with the support from the pork industry 
as well as State and Federal governments. After the initial fed-
eral ban (1963) on interstate shipment of virulent CSF virus 
or of feeder pigs and breeding stock vaccinated with CSF vac-
cines, use of MLV vaccines and inactivated vaccines continued 
until banned in 1969 (Lofflin, 2009; USDA, 2019). Most of 
the control policies were developed based on the early CSF re-
search findings of USDA scientists and veterinarians. Injection 
of hyperimmune anti-CSF serum plus CSF virus was used as 
a routine CSF control method for decades until CSF vaccines 
with reasonable efficacy were developed in the 1950s. Large 
scale field trials involving thousands of swine farms were con-
ducted to evaluate the field efficacy of anti-CSF biologics (vac-
cines and antiserum products). The plans and policies for CSF 
eradication in the United States were developed based on the 
knowledge regarding how the CSFV was transmitted. Other 
significant contributions included clinical trials with anti-hog 
cholera serum products, various inactivated CSF vaccines and 
MLV vaccines, and the development of fast and accurate diag-
nostic methods for CSF.
Actions and governmental regulations associated with CSF 
control in the United States played an important role in the 
development of animal health policies in general. Since the 
discovery that pigs injected with hyperimmune serum could 
be protected from CSF virus challenge in 1907 (USDA, 2019), 
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anti-hog cholera serum production and processing plants mush-
roomed in Kansas City and the rest of the Midwest (Lofflin, 
2009). Interestingly, pigs were not only an important food 
source for ordinary Americans 100 yr ago, they were also very 
important to the politicians. Then-President Woodrow Wilson 
attended National Swine Show (Figure 1A), and his Secretary 
of the U.S. Food Administration Herbert Hoover believed 
that food would help the U.S.  win World War I  and started 
a national campaign for greater swine production (Nebraska, 
2020). He said in 1917: “We need a ‘keep-a-pig’ movement in 
this country, and a properly cared for pig is no more unsanitary 
than a dog. Every pound of fat is as sure of service as every 
bullet, and every hog is of greater value to the winning of this 
war than a shell.”
Given the social and economic importance of pork produc-
tion in the United States at the beginning of the 20th century, 
perhaps it was not a surprise that one of the earliest anti-hog 
cholera serum plants in the Kansas City area was created by 
Mason Peters, a lawyer and former U.S. congressman in Kansas 
(Kansas, 1914). He saw the potential of this biological product 
(Figure 1B). Mason Peters “was one of the most active in the 
original research work for the practical use of this remedy to 
combat hog cholera.” Equally amazing is that an academic in-
stitution like Kansas State Agricultural College also owned and 
operated an anti-hog cholera serum plant from 1908 to 1948 
(Dykstra, 1952). The transgenerational significance of that 
serum plant location is obvious as the “Serum Plant Road” 
on Kansas State University campus today leads to USDA’s 
National Bio and Agro-defense Facility (NBAF) in which re-
search related to CSF will continue (Montgomery, 2019).
Furthermore, the Virus-Serum-Toxin Act, which enacted 
federal regulation of veterinary biologics in 1913, was passed 
largely because of public concerns over the safety and efficacy of 
veterinary vaccines from Europe and hog cholera products being 
produced and marketed across the country (USDA, 2020). The 
new law required the USDA to ensure that veterinary biologics 
(vaccines, bacterins, antiserums, and similar products) sold in the 
United States are pure, safe, potent, and efficacious.
The successful eradication of CSF in the United States 
was the result of a determined and comprehensive approach 
including 1) more than 60 yr of scientific research and devel-
opment on CSF virus and the disease management tools (anti-
serum products, vaccines, and diagnostics); 2)  science-based 
regulatory decisions from all levels of government; and 3) the 
public and private partnership of all stakeholders related to the 
swine industry. We can summarize the best-laid plan in CSF 
prevention and control (the U.S. story) as:
1. Know your enemy (the disease and pathogen) through sup-
porting innovative research.
2. Develop and implement science-based governmental pol-
icies at both state and federal levels.
Figure 1. Pigs were important animals to the President and other politicians 
100 yr ago. Shown are two advertisements in The Poland China Journal 
(January 10, 1917) that depicted the relationship between pigs and politicians 
in the early 20th century. (A) President Woodrow Wilson at the National 
Swine Show in 1916. (B) Former U.S. Congressman Mason S. Peters and 
his six sons formed the National Serum Company with seven serum plants 
around Kansas City.
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3. Ensure the cooperation of all stakeholders of the pork in-
dustry including pig producers, animal health companies, 
veterinarians, and regulatory agencies.
Why CSF is still endemic in Asia and how can it be 
eradicated in the future?
It has been clearly demonstrated that CSF can be eradicated 
with less ideal tools (vaccines and diagnostics) in a country with 
large and intensive swine production systems. Nevertheless, 
CSF remains one of the most devastating diseases of swine 
in many other large pork-producing countries such as China, 
Vietnam, Thailand, Japan, South Korea, and the Philippines. 
This phenomenon is intriguing as these countries have pro-
duced or have had access to the C-strain CSF vaccines that are 
affordable, available, safe, and efficacious against all known 
genotypes of the CSF virus.
With the development of better vaccines and faster and 
more accurate diagnostic assays over the last 20 yr, CSF en-
demic countries have more and superior technological tools 
for CSF control and eradication than the United States did 
in 1960 to 1978. Subunit vaccines based on CSFV structural 
protein E2 have been marketed since the 1990s and newer ver-
sions of E2 subunit vaccines have also been now manufactured 
and marketed by different companies in Asia (Blome, et  al., 
2017; Gong, et al., 2019). One of the distinct advantages of E2 
subunit vaccines is their intrinsic capability of differentiating 
vaccinated from infected animals in which infected pigs would 
produce antibodies against other CSFV structural proteins 
such as Erns (Madera et al., 2016; Wang et al., 2020).
The C-strain MLV vaccine is an attenuated live virus and 
can provide complete protection against wild-type CSFV 
with the onset of effective immunity just 5 d after vaccination 
(Graham et  al., 2012). The only drawback of this vaccine is 
that it is difficult to differentiate pigs vaccinated with C-strain 
from pigs infected with field strains of CSFV. This shortcoming 
may be overcome soon because a C-strain CSFV Erns-specific 
monoclonal antibody (mAb) has been recently generated by 
our group (Wang et al., 2020). A cELISA is being developed 
to differentiate pigs vaccinated with the C-strain vaccine from 
pigs infected with wild-type CSFV or unvaccinated pigs, based 
on the observation that the latter two groups of pigs do not 
produce antibodies that can compete with this C-strain Erns-
specific mAb. This is an example of a positive DIVA marker.
With the help and guidance from the Food and Agriculture 
Organization (FAO) and the World Animal Health Organization 
(OIE), many if  not all CSF endemic countries in Asia have 
developed national policies for CSF control and eradication 
(China, 2012; FAO and OIE, 2014). Thus, it is not the lack of 
technological tools and/or government policies that have hin-
dered the eradication of CSF in these CSF endemic countries. 
Because the C-strain vaccine can be cost-effectively produced 
and marketed or freely distributed to swine producers in China 
and other Asian countries, lack of resources (vaccines) does 
not seem to be the major constraint to control CSF, which is 
often the case in tackling a major disease epidemic such as the 
COVID-19 (McMahon et al., 2020).
There is no doubt that CSF outbreaks can be effectively 
controlled by routine and high coverage vaccination with the 
C-strain vaccine, but the success of this approach requires gov-
ernment support in providing sufficient and qualified field vet-
erinarians and establishing an effective disease diagnostic and 
epidemic information network. More importantly, the gov-
ernment at all levels (central and local) should provide suffi-
cient technical support and financial compensation to swine 
producers whose pigs might have to be culled due to localized 
CSF outbreaks. Furthermore, government, industry associ-
ations, and the media can also play an important role in raising 
public awareness that CSF can and should be eradicated soon. 
Without an effective eradication plan, CSF will continue to 
negatively affect general consumers due to pork price increase 
and overall inflation when pork production is disrupted by dis-
ease outbreaks.
Thus, the eventual eradication of CSF from CSF endemic 
countries may depend on whether and when all stakeholders 
of the pork industry can form a real partnership and work co-
operatively for the same goal. To make this partnership effective, 
pork producers and animal health companies also must equally 
contribute to control and eradication efforts. These efforts will 
include strict compliance with government regulations on vaccin-
ation and animal movement; eliminate production, marketing, 
and use of CSF vaccines when a vaccination ban is placed in 
effect in the final stages of a CSF eradication plan.
African Swine Fever
What is African swine fever?
Although CSF and ASF share similar clinical signs such as 
high fever, loss of appetite, lethargy, and high mortality rate, 
these two diseases are caused by two distinct and unrelated 
viruses. The CSFV is a small (12.3 kb) RNA virus with only 
four structural proteins, while the ASFV is a large DNA virus 
(170 to 190 kb genome) with more than 50 structural proteins 
(Schulz et al., 2017). Since ASF was first reported in Kenya, 
ASF research has been the focus for only a few laboratories in 
Europe after its first emergence in the 1960s. This might be par-
tially due to the observation that ASF was eradicated in most 
parts of Europe in the 1990s. The re-emergence of ASF in east 
European counties since 2007 sparked more interest in ASF re-
search (Borca et al., 2016), the urgency for and the intensity of 
ASF research are increased significantly worldwide only after 
the ASF outbreak was first reported in China in 2018 (Zhou 
et al., 2018). Since then, ASF outbreaks have occurred in many 
other pork producing countries in Asia including Vietnam, 
South Korea, Cambodia, Laos, the Philippines, and Indonesia 
(Figure  2). More recently, ASFV has been detected in wild 
boars in Belgium and Germany (USDA, 2020). Because there 
are significant knowledge gaps about ASFV and ASFV–host 
interactions, it is no surprise that safe and efficacious commer-
cial ASF vaccines have yet to be developed.
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Was an ASF outbreak in China/Asia inevitable?
Three conditions might explain why ASF research in 
China was not a priority before 2018: 1) limited preparations 
for ASF research—there were very limited high containment 
(biosafety level 3) research facilities in China that were avail-
able for animal studies on foreign animal diseases such as 
ASF; 2)  false security—CSF and foot and mouth disease 
(FMD), two other highly contagious and devastating swine 
viral diseases are largely controlled in China via mass vaccin-
ation; and 3) false optimism—because ASF has been largely 
eradicated in Europe in the 1990s, it was not hard to imagine 
that ASF could be controlled quickly by culling pigs infected 
with ASF virus. Consequently, research on ASF as a foreign 
animal disease was not carried out as a priority in China 
to develop the tools essential for the prevention and control 
of ASF.
Before the rapid spread of  ASF in China that was first re-
ported in August 2018, policymakers in China were aware of  the 
serious threat of  ASF and had implemented an ASF-specific 
national policy—“Technical Specification for Prevention and 
Treatment of  African Swine Fever” in 2015 (China, 2015). 
Based on online public reports (https://finance.huanqiu.com/
article/9CaKrnJY1uN and http://www.cpwnews.com/con-
tent-23-9199-1.html), the General Administration of  Customs 
of  China (GACC) and the Ministry of  Agriculture (MOA) or-
ganized several ASF-specific emergency response drills in nor-
thern provinces and cities including Inner Mongolia, Hebei, 
Beijing, and Tianjin in 2016 and 2017. The risk of  importing 
transboundary animal diseases associated with the “One Belt 
One Road” Initiative (BRI) was highlighted as the rationale 
behind these exercises.
Although no direct evidence that ASFVs were introduced 
to China via commercial activities of the BRI, there are two 
intriguing relevant observations: 1) the first ASF outbreak was 
likely started in mid-June (was confirmed on August 2, 2018) on 
a swine farm in the outskirts of Shenyang (Zhou et al., 2018), 
the provincial capital of Liaoning Province; and 2) on June 11, 
2018, the first convoy of six trucks and two buses supplying 
with fruits and vegetables returned from a 25-d round trip from 
Dalian, China to Novosibirsk, Russia. Shenyang is 400 km 
from Dalian and a likely stop on the road from Novosibirsk 
to Dalian (https://www.sohu.com/a/238415268_267831?_
f=index_pagerecom_417). However, what happened next 
was puzzling: the second ASF case was confirmed 12 d later 
in Zhengzhou (http://www.xinhuanet.com /fortune/2018-
08/16/c_1123281884.htm), which is 1300 km south of Shenyang.
It is even more troubling and puzzling that tens of millions 
of pigs were lost due to ASF outbreaks all over China and some 
Figure 2. Global distribution of ASF, 2005–2020. This map is based on data from the OIE World Animal Health Information system (https://www.oie.int/
wahis_2/public/wahid.php/Disease information/Diseaseoutbreakmaps?) and Global Disease Monitoring Reports (https://www. swinehealth.org/global-disease-
surveillance-reports/). The names of countries with ASF are given on the map. Countries with continuing ASF outbreaks were labeled with the year when the 
first outbreak was reported since 2005. Data not shown: the following countries reported new ASF outbreaks in 2019: Sierra Leone, Chad, Belgium, Hungary; 
and in 2020: Cote d’Ivoire, Nigeria, Kenya, Zambia, Namibia, South Africa, Greece, Bulgaria, Serbia, Slovakia, Poland, Lithuania, Latvia, Estonia, Ukraine, 
Romania, Moldova, Russia, China, Mongolia, Myanmar, Laos, Cambodia, Vietnam, Indonesia, Timor-Leste, Philippines, South Korea, and North Korea.
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of its neighboring countries in less than 1 yr. These losses prob-
ably eclipsed the total number of pigs lost on the entire planet 
to ASF over the previous 90 yr. ASF meetings in China were 
often packed with hundreds of swine producers with the hope 
to find a miracle weapon to control or prevent ASF on their 
farms (Figure  3). Without the help of a safe and efficacious 
commercial ASF vaccine, swine producers in China and the rest 
of Asia have quickly recognized the importance of biosafety 
and biosecurity in swine production over the last 2 yr.
How to develop a successful plan for ASF preven-
tion and control?
After ASF outbreaks started in China, swine producers 
quickly learned that, unlike CSF or FMD that could be effect-
ively controlled by mass vaccination, there is no commercial ASF 
vaccine in the world. Without a tool to implement a “vaccinate-
to-live” policy, millions of pigs were culled in the early days of 
ASF outbreaks in China. Although this control measure seems 
to be in line with OIE and FAO guidelines, the losses and disrup-
tion it created soon became unbearable for at least two reasons: 
1) the social and economic impact associated with the huge in-
crease of pork price in a few months after the number of pigs 
available for the market was reduced quickly and dramatically, 
and 2) the environmental risk associated with disposing of thou-
sands of pigs on farms in a short period of time.
Without an available safe and efficacious vaccine, swine 
producers quickly realized that they have to significantly im-
prove biosafety and biosecurity measures on farms to prevent 
the introduction of  ASFV, and use “targeted culling—pull 
the bad tooth” to remove ASFV infected pigs from the facility 
to avoid further disease spreading and to preserve the herd. 
“Reopening” some of  the infected farms for production be-
came possible after carrying out intensive disinfection of  the 
infected facility. In addition, significant changes have to be 
made in biosafety practices to minimize the risks associated 
with many factors associated with swine production. These 
risk factors include culled pigs, lagoons, pigs and feed pur-
chased from outside suppliers, selling pigs to others (trucks 
and personnel from outside vendors), drinking water, boots 
and coveralls, insects, rodents and pests on farms, swine 
semen, and use of  veterinary pharmaceuticals and vaccines. 
Implementing policies to incentivize employees to follow 
biosafety rules and remodeling the current facility for better 
biosafety control are also common practices for many swine 
operations. However, many of  these changes are very costly 
and can only be effectively managed by well-funded large op-
erations. Nevertheless, various “Reopening” or “Re-grow” 
plans have been developed and tested to raise pigs before a 
highly efficacious vaccine is available.
If  a successful plan for ASF prevention and control could 
be developed, it should resemble the plan that facilitated the 
U.S. eradication of CSF more than 40 yr ago. Briefly:
1. Know your enemy (the disease and pathogen) through sup-
porting innovative research.
 Invest strongly and continuously in research related to 
ASFV, ASFV–host interaction, point-of-contact diagnos-
tics, safe and efficacious vaccines, swine farm biosafety and 
biosecurity risk management systems, and high containment 
facilities that are suitable for ASF research.
2. Develop and implement science-based governmental pol-
icies at both state and federal levels.
 Develop and implement science-based animal disease out-
break emergency management policies that will encourage 
the full participation and support of pork producers and 
consumers: swine farmers, pork processing plants, and the 
public. These policies must consider: 1) what will happen if  
the government does not compensate swine producers for 
their loss due to ASF outbreaks? 2) how can swine farmers 
properly cull/dispose of thousands of pigs in a short period 
of time?, and 3)  how do the processing plants/slaughter-
houses deal with ASFV positive products?
3. Ensure the cooperation of all stakeholders including pig 
producers, animal health companies, veterinarians, regula-
tory agencies, social media, and the public.
 Because the public is a significant stakeholder of the pork 
industry, it is not enough to tell the public that ASFV does 
not infect people. Instead, the swine industry should educate 
the public that ASF outbreaks affect the livelihood of many 
parts of the society including swine producers, workers on the 
farm, grain and feed producers, pork processing plants, gro-
cery stores, truck drivers, animal health companies, restaur-
ants, international and regional pork/grain/feed importers and 
exporters, and all consumers of pork products. Animal health 
companies should only manufacture and sell safe and effica-
cious ASF vaccines, and swine producers should only use au-
Figure 3. ASF meetings for swine producers were held frequently in China 
during the first half  of 2019. Shown here was an ASF meeting at Nanning, 
China on March 20, 2019. While 500 people pre-registered, 800 swine farmers 
and animal health professionals showed up at this “Protect Pigs from ASF 
and Survive” meeting. The focus of this meeting was on-farm practices that 
can minimize the biosafety and biosecurity risks associated with swine pro-
duction. Photo courtesy of Mr. Yuanfei Gao of Yangxiang Group, the organ-
izer of this ASF meeting.
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thorized ASF vaccines. Veterinarians should employ only field 
tested, effective immunization, and biocontrol practices. Ad-
ditionally, ASFV positive products should not be produced, 
transported, sold, or consumed by anyone. Swine production 
security is a “weakest-link in the chain” problem. Therefore, 
the only way to achieve long-lasting security of the system is to 
improve the strength of the weakest link through full cooper-
ation and regulatory compliance among all stakeholders.
Future Prospective
CSF and ASF are swine viral diseases with high conse-
quential social and economic impacts in endemic countries. 
Successful prevention and control of ASF and CSF requires 
not only safe and efficacious vaccines and fast and accurate 
diagnostic tools but also science-based government policies 
that ensure the cooperation of all stakeholders of the swine in-
dustry. Science and technology alone are not enough without 
the effective partnership of the public.
Despite recent devastating outbreaks of ASF and CSF in 
Asia, the countries of North America and Europe demon-
strated decades ago that ASF and CSF can be eradicated with 
proper government policy and adequate scientific and techno-
logical tools. The world has indeed changed since then, notably 
with ever-increasing high-density swine production and global-
ization, which demands more innovative approaches to solve 
new problems:
1. What is the best way to cull/dispose of thousands of pigs in 
a short period of time in a restricted area to take into con-
sideration of animal welfare, economic and environmental 
impact, and technical feasibility?
2. Because large quantities of various disinfectants are used to 
inactivate the ASFV on swine farms, the negative impacts of 
these biosafety measures on environment, food safety, and 
human health should be carefully investigated.
3. The transboundary nature of emerging and re-emerging 
high consequence animal infectious disease threats requires 
global cooperation not only in outbreak management, but 
also in research for a broader biomedical, social, and eco-
logical understanding of disease systems.
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